aGvHD is a major cause of morbidity and mortality following allogeneic hematopoietic stem cell transplantation. The patients (N=173) treated in EAP previously failed 1 to 6 aGvHD systemic treatment ...
Structure Therapeutics recently reported positive topline Phase 2b and related ACCESS program data for its oral GLP-1 agonist aleniglipron in adults with obesity or overweight, showing clinically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback